search

Active clinical trials for "Lymphoma, Follicular"

Results 581-590 of 600

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With...

Hematopoietic/Lymphoid CancerAccelerated Phase Chronic Myelogenous Leukemia155 more

RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignancies previously treated with donor stem cell transplant.

Completed11 enrollment criteria

DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma...

Lymphoma

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying DNA isolated from blood samples to see how well it influences response to rituximab in patients with follicular lymphoma treated on clinical trial ECOG-E4402.

Completed8 enrollment criteria

Causes of Death in Follicular Lymphoma: a Single Center Retrospective Analysis

This Study Describes the Different Causes of Death in 237 FL Patients

Background.Although the life expectancy of patients with FL has recently increased, notably since the introduction of rituximab in combination with chemotherapy, little is known regarding the precise causes of patients death. Patients and methods'. This study describes the different causes of death in FL patients among followed since 2000 at Lyon University Hospital, centre Léon Bérard and Mayo Clinic. The causes of death will be classified as related to lymphoma progression, treatment-related toxicity (including TRM and secondary myelodysplastic syndrome/acute myeloid leukemia), secondary neoplasias, or other.

Completed3 enrollment criteria

CD180 Overexpression in Follicular Lymphoma

Follicular Lymphoma

Background:Altered Toll-like receptor (TLR) expression levels and/or mutations in its signaling pathway (such as MyD88 mutation) contribute to the pathogenesis of lymphoproliferative disorders (LPD). CD180 is an orphan member of the TLR family that modulates the signaling of several TLRs, but only limited studies have evaluated its expression by flow cytometry (FCM) in LPD. Methods: Using a multiparameter FCM approach, biologists have assessed CD180 mean fluorescence intensity (MFI) in lymph nodes (LNs) and peripheral blood (PB) samples obtained from patients with follicular lymphoma (FL; LN/PB, n=44/n=15), chronic lymphocytic leukemia (CLL, n=26/n=21), mantle cell lymphoma (MCL, n=13/n=17), and marginal zone lymphoma (MZL, n=16/n=12). Specimens from non-tumoral PB and LN (n=8/n=12) were used as controls.

Completed7 enrollment criteria

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or...

Chronic Lymphocytic LeukemiaFollicular Lymphoma

This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization. The study population comprises patients with approved local indications chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical practice after launch.

Completed6 enrollment criteria

Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1

Follicular Lymphoma

The primary objective is to evaluate the safety profile and tolerability of rituximab in combination with different chemotherapy regimens.

Completed14 enrollment criteria

An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday...

LymphomaB-Cell2 more

This observational study aims to assess the therapeutic responsiveness of MabThera SC in patients with malignant lymphomas under everyday clinical practice conditions. Patients with previously untreated CD-20 positive follicular non-Hodgkin's lymphoma (NHL) or previously untreated CD-20 positive diffuse large B-cell lymphoma (DLBCL) who are planned for therapy with MabThera SC according to the assessment of the physician will be prospectively enrolled for observation. No study specific measures are required; treatment and documentation will be performed according to usual clinical practice.

Completed6 enrollment criteria

Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study)

LymphomaFollicular

The F2-study is a complement of the previous studies of the Follicular Lymphoma Prognostic Factors Project which permitted the development of the Follicular Lymphoma International Prognostic Index (FLIPI). The F2-study is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed Follicular Lymphoma patients, and its purposes are to validate the FLIPI and to verify whether a prognostic collection of data would allow the development of a more accurate prognostic index.

Completed5 enrollment criteria

Study of Lymphoma in Asia

LymphomaFollicular7 more

Background: - Lymphoma rates in Asia have been lower than in the West, but rates have been rising in recent years. Most studies of lymphoma patients have been conducted in the West. Less information is available about the factors that might contribute to the rise of lymphoma in Asia. Researchers want to collect medical and personal histories and samples from people who have recently been diagnosed with lymphoma. This information will help them study possible reasons for this increase. Objectives: - To collect samples and histories as part of an introductory study of lymphoma in Asia. Eligibility: People between 18 and 79 years of age who have entered study hospitals in Hong Kong, Taiwan, and mainland China for treatment for any type of lymphoma. Healthy volunteers between 18 and 79 who have never had lymphoma. Design: Participants will be screened with a physical exam and medical history. They will provide blood samples and cheek cell samples for testing. Participants will complete a questionnaire about their personal health history. They will answer questions about exposures to chemicals like pesticides. They will also be asked about family medical history and work and residential history. Finally they will answer questions about lifestyle factors like diet and exercise. They will give permission for the researchers to see their medical records. Researchers will also have access to any tumor samples collected as part of treatment.

Completed3 enrollment criteria

Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI

LymphomaNon Hodgkin Lymphoma1 more

18F-FDG PET/MR imaging protocol integrating advanced MR vascular imaging sequences, along with computerized quantitative methods for data analysis, is expected to serve as an objective tool for assessment of lymphoma patients. The aim of this prospective study is to develop an automatic artificial intelligence-based tool for the assessment of early response to treatment and evaluation of residual masses in patients with lymphoma. Specific objectives are: To evaluate the added value of 18F-FDG PET/MRI compared with PET/CT in imaging lymphoma. To optimize PET/MR imaging protocol for lymphoma assessment. To develop an automated tool for staging patients with lymphoma. To develop an automated method for early prediction of response to therapy and prognosis in patients with lymphoma. To develop an automated non-invasive tool for discriminating benign from active residual masses at end of treatment in patients with lymphoma.

Unknown status5 enrollment criteria
1...585960

Need Help? Contact our team!


We'll reach out to this number within 24 hrs